Tag: Roots Analysis
More than 80 companies required expertise to design and manufacture different types of labels for use in medical devices
Owing to the ever-increasing number of medical devices along with the rising associated complexities and stringent guidelines issued by various regulatory authorities, the global medical device labeling market is likely to grow at stable rate.
The medical device label contract manufacturing market is projected to grow at an annualized rate of ~9.8%- Roots Analysis
Roots Analysis has done a detailed study on “Medical Device Labels Technology Market, 2019-2030 covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
The medical device label contract manufacturing market - Roots Analysis
Outsourcing the manufacturing of labels is a popular trend among medical device developers, enabling such companies to leverage the advanced capabilities of CMOs, while focusing on the core aspects of product development
over 350 such drug candidates are being evaluated for the treatment of a wide variety of disease - Roots Analysis
Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration.
The oligonucleotide synthesis, modification and purification services market - Roots Analysis
The applications of oligonucleotides are vast, even beyond the life science / pharma sector; however, owing to complexities associated with the synthesis and processing of these molecules, such operations are usually outsourced to capable CMOs
HPAPI and cytotoxic drugs contract manufacturing market is projected to reach USD 25 billion- Roots Analysis
Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers
Patient Recruitment and Retention Services, 2019-2030 - RootsAnalysis
A detailed assessmentof the current market landscape, including information on drug developer(s
Patient Recruitment and Retention Services Marker
A steadily increasing demand for study participants and the complexities associated with patient enrollment has imposed a significant burden on drug developer companies
The patient recruitment and retention services market - RootsAnalysis
Roots Analysis has done a detailed study on Patient Recruitment and Retention Services Marker, 2019-2030.”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
The patient recruitment and retention services market- Rootsanalysis
A steadily increasing demand for participants in clinical research studies, coupled to the complexities associated with patient enrolment, have prompted drug / therapy developers to outsource this process to specialty service providers
More than 100 industry players and over 60 non-industry players currently
Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years.
Growing at an annualized rate of over 16.5%
Theapproval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased theinterest of pharma stakeholders in cell therapies; further, owing to thetechnical challenges in this field, outsourcing manufacturing operations hasbecome a necessity
The cell therapy manufacturing market is projected to grow
Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract service providers may need to strengthen their capabilities and expand available capacity.
The cell therapy manufacturing market is estimated - RootsAnalysis
Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers.
the cell therapy manufacturing market is estimated
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies.
